Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : ajtj's Post-Lobotomy Market Charts and Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Qone0 who wrote (83141)	12/8/2023 11:40:52 AM
From: Sun Tzu	2 Recommendations Recommended By ajtj99 Qone0 Read Replies (1) \| Respond to of 97016

Proof of your experience just arrived U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease PUBLISHED FRI, DEC 8 202311:19 AM ESTUPDATED 11 MIN AGO Angelica Peebles @IN/ANGELICAPEEBLES/ @ANGELICAPEEBLES SHAREShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email KEY POINTS The U.S. Food and Drug Administration has approved Casgevy, the first gene-editing treatment to be marketed in the country. Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans. Vertex Pharmaceuticals and CRISPR Therapeutics co-developed the one-time treatment that could cost around $2 million per patient. In this article VRTX-3.66 (-1.04%) CRSP-2.40 (-3.42%)